Non-interventional, Post Marketing Surveillance Study of Xultophy™ (Insulin Degludec/Liraglutide) to Evaluate Long Term Safety and Efficacy in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in India

Sponsor
Novo Nordisk A/S
Study ID
NCT03070704
Status
Withdrawn

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • insulin degludec/liraglutide — DRUG
    Patients will be treated with commercially available Xultophy™ (insulin degludec / liraglutide) according to routine clinical practice at the discretion of the treating physician

Study Details

This study is conducted in Asia. The aim of this study is to evaluate long term safety and efficacy in patients with type 2 diabetes mellitus in routine clinical practice in India.

Key Dates

Start date
Aug 16, 2017
Status verified
Aug 2017
Primary completion
Mar 1, 2019
Completion
Aug 16, 2019

Study Design

Enrollment
0 participants (actual)

Arms

  • Arm: Insulin degludec /liraglutide

Primary Outcome Measure

Incidence of treatment emergent Adverse Events (AEs) [ Time Frame: Year 0-1 ]

Related Studies